Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Unigene Sets Up China Biotech JV with Shijiazhuang Pharma

publication date: Jan 7, 2008

Unigene will establish a joint venture in China with Shijiazhuang Pharma that will use a biologic process to produce Fortical, a nasal spray formulation of calcitonin salmon indicated for osteoporosis. Currently, Unigen employs chemical synthesis to manufacture the drug. According to Shijiazhuang Pharma, the biologic process, using genetic fermentation technology, is much more efficient. Unigene and Sjihiazhuang will each invest $15 million in the JV. More details...

Stock Symbols: (OTCBB: UGNE) (NYSE: GSK) (NYSE: NVS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here